Insulet Corporation (PODD)

NASDAQ: PODD · IEX Real-Time Price · USD
263.06
-3.99 (-1.49%)
At close: Aug 8, 2022 4:00 PM
267.47
+4.41 (1.68%)
After-hours: Aug 8, 2022 5:40 PM EDT
-1.49%
Market Cap 18.26B
Revenue (ttm) 1.18B
Net Income (ttm) 34.60M
Shares Out 69.40M
EPS (ttm) 0.67
PE Ratio 392.63
Forward PE 204.08
Dividend n/a
Ex-Dividend Date n/a
Volume 357,497
Open 267.05
Previous Close 267.05
Day's Range 260.42 - 272.51
52-Week Range 181.00 - 324.81
Beta 0.72
Analysts Buy
Price Target 271.54 (+3.2%)
Earnings Date Aug 4, 2022

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorpo... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date May 15, 2007
CEO Shacey Petrovic
Employees 2,300
Stock Exchange NASDAQ
Ticker Symbol PODD
Full Company Profile

Financial Performance

In 2021, Insulet's revenue was $1.10 billion, an increase of 21.49% compared to the previous year's $904.40 million. Earnings were $16.80 million, an increase of 147.06%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is 271.54, which is an increase of 3.22% from the latest price.

Price Target
$271.54
(3.22% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management wi...

Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates

Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced fin...

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its...

Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced pla...

7 Stocks to Buy That Could Make You a Millionaire

These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments.

Other symbols: BRKRETSYMARRHSEDGTXG

Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5

Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Childr...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new...

Insulet (PODD) to Expand Base in Malaysia With New Facility

The new manufacturing facility by Insulet (PODD) is set to have approximately 400,000 square feet of manufacturing space.

Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management wi...

Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host a groundb...

DexCom stock leads S&P 500's premarket gainers after denying merger talks, and Insulet stock drops

Shares of DexCom Inc. DXCM, +5.35% surged 8.1% to pace the S&P 500's SPX, -0.37% premarket gainers, after the diabetes care company said it was not currently in "active discussions" regarding a merger. ...

Other symbols: DXCM

Why Insulet Stock Is Soaring This Week

The company is reportedly in discussions with Dexcom about a potential merger.

PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition

Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company. The post PODD Stock Pops 7% as DexCom Considers Insulet Corporati...

Other symbols: DXCM

Insulet's stock is up on Bloomberg report that it may be acquired by Dexcom

Shares of Insulet Corp. PODD, +2.08% gained 9.9% in premarket trading on Tuesday, the day after Bloomberg reported that the company is in talks to be acquired by Dexcom Inc. DXCM, +0.84% , citing anonym...

Other symbols: DXCM

Insulet (PODD) Q1 Earnings Surpass Estimates, Margins Grow

Robust adoption of Omnipod DASH and record new customer starts have contributed to Insulet's (PODD) Q1 performance.

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'

Insulet Corporation (NASDAQ: PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million,...

Insulet (PODD) Tops Q1 Earnings and Revenue Estimates

Insulet (PODD) delivered earnings and revenue surprises of 73.91% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet Announces CEO Transition

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced tha...

Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced fin...

Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD

The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.

Other symbols: CAHMCK

Refresh Your Portfolio by Dumping These 5 Toxic Stocks

Get rid of toxic stocks like GoodRx (GDRX), Insulet (PODD), Vonage (VG), AppLovin (APP) and Embraer (ERJ) to avoid portfolio bleeding.

Other symbols: APPERJGDRX

Insulet's 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the...

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new...

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

Investors are optimistic about Insulet (PODD) on robust uptake of the Omnipod system and bullish guidance.